Register Now - Every Drop Matters: Reducing Product Loss in Sterile Filtration
|Articles|February 3, 2016

LabConnect Builds New Biorepository Facility

LabConnect built a biorepository facility in Tennessee.

LabConnect, a Seattle-based provider of laboratory services to biopharmaceutical, medical device, and contract research organizations, has built a new biorepository facility to expand services and better meet the evolving needs of the industry.

According to a Feb. 3, 2016 press announcement from the company, LabConnect’s new, 5000-square-foot biorepository in Johnson City, TN, includes space for ambient, refrigerated, cold (-20 °C), and ultra-low temperature (-70 to -80 °C) storage as well as liquid nitrogen vapor phase storage (-190 °C).

“Proper sample management is essential to both today’s and tomorrow’s clinical trials,” said Eric Hayashi, LabConnect president and CEO, in the press release. “Researchers depend on the integrity and availability of their stored biospecimens to retest them to verify trends or unexpected results, or for later retrieval to support specific biomarker research.”

The facility includes storage capacity for more than 8 million samples, fully validated and mapped backup freezers and generators, redundant HVAC systems, whole building and biorepository security systems, and a temperature monitoring system for all freezers and refrigerators with a 21 CFR Part 11 compliant audit trail. LabConnect also tracks sample locations and consolidates data within a centralized database. 

Source: LabConnect


Related to this article

The BioPharm Brief: Long-Term Survival Data for a PD-L1/4-1BB Bispecific, Celldex Exits Atopic Dermatitis, and a Fc-Fusion GLP-1 Goes Global
Leads Biolabs details survival data and 2027 ADC combination plans for its PD-L1/4-1BB bispecific opamtistomig, Celldex Therapeutics ends its atopic dermatitis program for anti-KIT antibody barzolvolimab after a phase 2 miss, and Innogen licenses its Fc-fusion GLP-1 receptor agonist efsubaglutide alfa to Arcera Life Sciences for international markets.